Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?
Related Questions
Would you consider adding metformin to the regimen of a diabetic patient with a benign thyroid nodule to decrease its volume?
Does papillary thyroid cancer with extensive squamous differentiation require specialized treatment beyond RAI and TSH suppression?
How do you counsel breastfeeding women on their limitations post radioactive iodine ablation for thyroid cancer treatment?
Statistically speaking, approximately what percentage of thyroid nodule FNA biopsies are Bethesda category 1 (= nondiagnostic or unsatisfactory), and what percentage are indeterminate (Bethesda category 3 and 4)?
Do you recommend repeat TSH testing after a patient switches from brand-name to generic levothyroxine?
What factors do you consider when deciding between RFA and surgery for a patient with a benign thyroid nodule causing dysphagia?
For patients with low risk, differentiated thyroid cancer, how do you navigate the decision between less aggressive treatments, such as lobectomy alone without radioactive iodine, and more aggressive strategies?
How do you approach the use of supraphysiologic T4 doses in patients with intermediate- and high-risk differentiated thyroid cancer, considering that elevated FT4 levels have not been linked to progression-free survival in recent clinical data?
If a patient requires more than 5 mg per day of methimazole long term do you recommend alternative treatment options such as radio-iodine ablation or surgery?
Should a different weight-based dosing algorithm for levothyroxine therapy be considered in women versus men given higher incidence of iatrogenic thyrotoxicosis in women?
